Incidence of Factor IX Inhibitor Development in Severe Haemophilia B Patients Treated with only one Brand of High Purity Plasma Derived Factor IX Concentrate

Summary

Fifteen previously untreated patients (Pups) with severe haemophilia B (factor IX activity ≤ 2 U/dl) only treated with one brand of plasma-derived high purity factor IX concentrate (FIX LFB) were studied. Age at first injection varied from 1 to 137 months and follow-up since this first injection from 21 to 86 months (median: 35). Cumulative exposure days (CED) were from 4 to over 100 (median: 26). Among these 15 Pups only one developed an inhibitor. Mutation analysis performed in all patients showed total gene deletion in the patient with inhibitor, partial gene deletion in another one, and missense mutations in 9 families. Mutation was not found in one patient. Actually, according to the data already published, only two patients were at high risk for inhibitor development in our population. Our study, although rather small, confirms the previously reported low incidence of inhibitors in haemophilia B. Large studies on incidence of FIX inhibitors are indeed difficult to perform, due to both the overall small number of severe haemophilia B patients and the low incidence of FIX inhibitors. Consequently, the impact of bias, such as prevalence of different types of gene defects in a given population, is major. Therefore, any study, dealing with incidence of FIX inhibitors in severe haemophilia B should report, for each patient, the type of gene defect.

Keywords

Haemophilia B - factor IX concentrate - inhibitor to factor IX - gene defect

• References

• 1 Sultan Y. the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67: 600-2.
• 2 Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B; results of a large-scale North American survey. Haemophilia 1996; 2: 28-31.
• 3 Briët E. Factor IX inhibitors in haemophilia B patients; their incidence and prospects for development with high purity factor IX products. Blood Coagul Fibrinol 1991; 2 (Suppl. 01) 47-50.
• 4 Ljung R, Petrini P, Lindgren AC, Tengborn L, Nilson IM. Factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 1550.
• 5 Ehrenforth S, Kreuz W, Scharrer I, Linda R, Funk M, Güngor T, Krackhardt B, Komhubert B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
• 6 Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, Miller RT, Pasi J, Rivard GE, Sommer SS, Katz J, Bergmann F, Ljung R, Lusher JM. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-7.
• 7 Ewenstein BM, Takemoto C, Warrier I, Luscher J, Saidi P, Eisele J, Etinger LJ, DiMichele D. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 1115-6.
• 8 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheilbel E, White G, Lee M. A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-35.
• 9 Lusher JM, Arkin A, Abilgaard CF, Schwartz RS. the Kogenate Previously Untreated Patients study group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia B: safety, efficacy and development of inhibitors. N Engl J Med 1993; 328: 453-9.
• 10 White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost 1997; 78: 261-5.
• 11 Burnouf T, Michalski C, Goudemand M, Huart JJ. Properties of a highly purified human plasma factor IX:C therapeutic concentrate prepared by conventional chromatography. Vox Sang 1989; 57: 225-32.
• 12 Goudemand J, Marey A, Caron C, Wibaut B, Mizon P. Clinical efficacy of highly purified SD treated factor IX concentrate prepared by conventional chromatography. Transfusion Med 1993; 3: 299-305.
• 13 Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting test. J Lab Clin Med 1953; 41: 637-47.
• 14 Parquet-Gernez A, Mazurier C, Amiral J, Martinoli JL. Assay of factor IX antigen using an enzyme immuno assay. Thromb Res 1984; 35: 703-12.
• 15 Kasper CJ, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, Mc Millan CW, Pool JG, Shapiro SS, Shulman NR, Van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
• 16 Shapiro AD, Ragni MV, Lusher JM, Culbert S, Koerper MA, Bergman GE, Hannen MM. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. Thromb Haemost 1996; 75: 30-5.
• 17 Ljung RCR. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Haematol 1995; 94 (Suppl. 01) 49-52.
• 18 Abshire T, Shapiro A, Gill J, Pasi J, Courter S. Recombinant factor IX (rFIX) in the treatment of previously untreated patients (Pups) with severe or moderately severe hemophilia B. Haemophilia 1998; 4: 229.
• 19 High KA. Factor IX: molecular structure, epitopes and mutations associated with inhibitor formation. In: Inhibitors to coagulation factors. Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC. (eds). New York: Plenum Press; 1995: 79-86.
• 20 Giannelli F, Green PM. The molecular basis of haemophilia A and B. Bailliere’s Clinical Haematology Bailliere Tindall eds 1996; 9: 211-28.
• 21 Gianelli F, Green M, Sommer SS, Poon MC, Ludwig M, Schwaab R, Reitsma PS, Goossens M, Yoshioka A, Brownlee G. Haemophilia B (sixth edition): a data base of point mutations and short additions and deletions. Nucl Acids Res 1996; 24: 103-18.